Investing in unprofitable companies like Salesforce.com can be profitable, but caution is advised due to the risk of cash burn. Compass Therapeutics (NASDAQ:CMPX) had a 3.7-year cash runway as of March 2024, but its increasing cash burn rate raises concerns.